Skip to main content

Recombinant Human IGFALS/ALS Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9917-IA

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
9917-IA-050

Key Product Details

Source

CHO

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human IGFALS/ALS protein
Ala28-Cys605, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala28

Predicted Molecular Mass

64 kDa

SDS-PAGE

76-88 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
In the presence of Recombinant Human IGFBP-3 (Catalog # 675-B3), immobilized Recombinant Human IGFALS/ALS (0.5 µg/mL, 100 µL/well) can bind Recombinant Human IGF-I (Catalog # 291-G1) with an ED50 of 15-90 ng/mL.

Scientific Data Images for Recombinant Human IGFALS/ALS Protein, CF

Recombinant Human IGFALS/ALS Protein Binding Activity

Recombinant Human IGFALS/ALS Protein Binding Activity

Immobilized Recombinant Human IGFALS/ALS (Catalog # 9917-IA) binds to Recombinant Human IGF-1 (Catalog # 291-G1) in the presence of Recombinant Human IGFBP-3 (Catalog # 675-B3). The ED50 for the binding is 15-90 ng/mL.
Recombinant Human IGFALS/ALS Protein SDS-PAGE

Recombinant Human IGFALS/ALS Protein SDS-PAGE

2 μg/lane of Recombinant Human IGFALS was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 76-88 kDa.

Formulation, Preparation and Storage

9917-IA
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: IGFALS/ALS

IGFALS (Insulin-like growth factor-binding protein complex acid labile subunit) or ALS (Acid labile subunit) is an 84-86 kDa glycoprotein member of the leucine rich repeat superfamily of molecules. It is secreted by hepatocytes in response to growth hormone stimulation, and forms a 140-150 kDa ternary complex with IGFBP3 (or IGFBP5) and IGF-I (1, 2). This complex increases the half-life of IGF-I and retains it in the circulation for use in multiple tissues. Natural variants of IGFALS/ALS have been found in idiopathic short stature in children (3, 4). Mature human IGFALS/ALS is 578 amino acids (aa) in length (aa 28-605). It contains twenty-one 20-23 aa LRRs that participate in protein-protein interactions. Structural studies have predicted the molecule to be a torus with a cluster of negative charge on the inside (5). Over aa 28-603, human IGFALS/ALS shares 79% and 78% aa identity with mouse and rat IGFALS/ALS, respectively.

References

  1. Belgorosky A. and Rivarola M.A. (1999) Horm. Res. 52:60.
  2. Fofanova-Gambetti O.V. et al. (2009) Horm. Res. 71:100.
  3. Domené, H.M, et al. (2013) Horm. Res. Paediatr. 80:413.
  4. Martucci, L.C. et al. (2016) Mol. Cell. Endocrinol. 429:19.
  5. Janosi, J.B.M. et al. (1999) J. Biol. Chem. 274:23328.

Long Name

IGF-binding Protein Acid Labile Subunit

Alternate Names

ACLSD, ALS

Entrez Gene IDs

3483 (Human); 16005 (Mouse)

Gene Symbol

IGFALS

UniProt

Additional IGFALS/ALS Products

Product Documents for Recombinant Human IGFALS/ALS Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IGFALS/ALS Protein, CF

For research use only

Loading...
Loading...
Loading...